We studied the mode of action of the low molecular weight heparin PK10169 and two of its constituent fractions: EMT 966 High Molecular Weight Fraction and EMT 967 Low Molecular Weight Fraction.
Introduction
Recently we developed a method that enables us to estimate the course of prothrombinase activity in clotting plasma (1). This method allowed us to discern the existence of two different types of heparin according to their different modes of action on thrombin generation in plasma (2, 3) . The S type heparins that, like standard heparin, act mainly by thrombin scavenging and the P type heparins that, like the AT III binding pentasaccharide (2, 3) are inactive towards thrombin but inhibit prothrombinase in plasma. From preliminary experiments it appeared that PK10169 was neither an S or an P heparin, but showed intermediate behaviour. It thus imported to know if this was due to an intrinsic property of one species of heparin molecule or due to PK10169 being a mixture of S and P type heparins.
Furthermore, in platelet rich plasma (PRP) some heparins are more susceptible to neutralization by platelet factor 4 than others. Again, we wanted to investigate whether a poorly active heparin fraction could influence the action of an active fraction via platelet factor 4 neutralization.
Materials and Methods

Materials
The chromogenic substrate for thrombin was H.D-Phe-Pip-Arg-pNA (52238) from KABI, Sweden. Kaolin was "Kaolin l6ger" provided by B L B Laboratoires du Bois de Boulogne (Putcaux-France) The heparins were supplied by Pharmuka Laboratories (France) PK10169 is obtained by alkaline hydrolysis of the benzylic ester of heparin. According to the manufacturer PK10169 is identical to the commercially availablc Enoxaparin/Lovenox@ EMT 966 and EMT 967 are prepared by gcl filtration of PK10169 on ultrogel AcA206 roughly one third of PK 10169 was in the EM 967 fraction and two thirds in EMT 966. The 4th lnternational Standard for Heparin(4th l.S.H.) was from the National Institute for Biological Standards and Control. The averagc molecular weight, antifactor lla and antifactor Xa activities, given by the manufacturers are indicated in Thble 1. These activities were measured as described inYinazzer and Woler (4).
Plasma
Blood from healthy donors was collected on 0 13 M trisodium citrate; nine parts of blood to one part of citrate solution A first and a second centrifugation were perfbrmed at 3,000 x g, at 15" C for 15 minutes. A third centrifugation was done at 4'C, for t hour at 23,000 x g The platelet free plasma thus obtained was stored at -80'C It was checked that the clotting factors and the antiproteases were in the normal range.
Defibrinated plasma was obtained by mixing an aliquot of plasma with l:50 volume of a reptilase solution, letting a clot form for 10 min at37" C and keeping the clotted plasma at 0" C for 10 min. The fibrin formed was discarded by centrifugation (10 min, 5,000 x g, 4' C) or by winding it on a small plastic spatula. The concentration of factors II, VII, VIil, IX, X, XI and XII did not significantly change by the reptilase treatment as has been shown before (1).
Proteins
Rcptilase was obtained from Laboratoires Stago (Asnidres, France), a solution was obtained according to the instructions of the manufacturer Soybean trypsin inhibitor (batch No 43 F-800) was obtained from Sigma (St. Louis, USA). Staphylocoagulase was obtained from Laboratoires Stago (Asnidres, France) and preparcd according to the instructions of the manufacturer Coagulation factors were purificd as indicated in Bdguin et al. (3) . Human AT III was prepared by polyethylenc glycol precipitation and heparin-scpharose affinity chromatography (5) followed by ionexchangc chromatography to remove the heparin (6) Determination of Prothrombinase Activity in Plasma
To 200 pl of defibrinated plasma is added 50 pl of 0 05 M Tiis-HCl, 0.1 M NaCl, 0 5 mg/ml ovalbumin, pH 7.35 containing heparin at the desired concentration and incubated for -5 min at 37" C At zero time. thrombin generation is started by the addition of 50 pl of a solution containing 100 mM of CaCl2 and a trigger of coagulation For the extrinsic system this is human brain thromboplastin, final dilution 1:240, for the intrinsic system 1 pM phospholipid and 0 25 mg kaolin (final concentrations). At intervals a 10 pt aliquot of the mixturc is sampled into a disposablc plastic cuvette containing 0.465 pl of 0.05 M Tris-HCl, 0.1 M NaCt, 20 mM EDTA, 0.5 mg ovalbumin/ml, pH 7 90 and 25 pl of 52238 (a mM) prewarmcd for at least 5 min at 37" C. After 120 seconds the reaction in the cuvette is stopped by adding 300 pl of concentrated acetic acid. The cuvcttes are read at 405 nm in a LKB Ultrospcc II spectrophotometer. The amidolytic activities in the plasma samples were calculated fiom the O.D. r'eading and expressed as the equivalent concentration of thrombin The generation of prothrombinase activity was calculated from the amidolytic activity curvc with the aid of a computer program as described previously (1). Briefly, the observed amidolytic activity is the sum of thrombin activity and the activity of o2M-thrombin complex The rate of thrombin generation at any momcnt is the sum of two processes: a) the conversion of prothrombin into thrombin by prothrombinase and b) the decay of thrombin by the action of plasma protease inhibitors. The rate of inhibition of thrombin at any time can be calculated from the concentration of thrombin at that moment and the pseudo first order rate constant of inhibition of thrombin by antithrombin III (k1) and o2-macroglobulin (k2). The rate of prothrombin activation (prothrombinase activity) then can be calculated from the observed rate of generation of amidolytic activity and the rate of thrombin inhibition
Determination of the Pseudo First Order Rate Constant of Inhibition of Thrombin in Plasma
Defibrinated plasma (200 pl) was incubated with 24 pl of buffer containing 0.05 M Tiis-HCl, 0.1 M NaCl, 0 5 mg ovalbumin/ml, pH 7 35 Thrombin generation was started as described in the previous section Two minutes after the peak activity of thrombin, 10 pl of Soybean Tiypsin Inhibitor (SBTI) solution (10 mg/ml) was added, together with 16 pl of buffer that contained thc heparin to be testcd SBTI at this concentration was shown to stop completely and instantaneously thc activity of prothrombinase and not to influence the acti.vity of thrombin (1). At suitable time intervals after addition of the SBTI solution, 10 pl aliquots of the incubation mixturc were added to cuvettes to measure residual thrombin activity as described The pseudo first order ratc constant of inhibition of thrombin generatcd in plasma was calculated by fitting the data to Ct:Cn+Coe-(kr+k'])t wherc C, is the thrombin activity at time t, Cp is the steady endlevel activity, C. + CR is the thrombin activity at the time of SBTI addition, k1 is the AT Ill-dependcnt decay constant of inhibition of thrombin, k2 is thc decay constant of inhibition of thrombin by o2-macroglobulin (42-M). The ratio of k1 to k2 is determined as the ratio of thc amounts of thrombin complexed with AT III and n2-M as described before (1).
First order rate constants in plasma were obtained as indicated above. In purified systems they were derived from the semi-logarithmic decay of factor activity in the presence of AT III and heparin at the conccntration indicated (Thbles 2 and 3).
The second order ratc constants were obtaincd from the tirst order rate constants by dividing through the AT III-heparin concentration prevailing in the experiments.
Results
Effect on the Decay of Thrombin Generated in Plasma
In Fig. 1 we see that with regard to their action on thrombin the low molecular weight heparins (LMWH) appear in two groups: those such as EMT 966 and PK10169 that, like standard heparin, do increase the AT III dependent breakdown constant (k1) of endogenous thrombin and EMT 967 that does not. It is seen that there is a rectilinear relationship between the concentration of heparin and the decay constant of thrombin for EMT 966, PK10169 and standard heparin. From the slopes of these lines the second order rate constants of thrombin inactivation in PPP can be calculated (Table 2 ). These second order rate constants enable us to compare the antithrombin activity in plasma of different LMW heparin on a weight basis and their relation to the activity of UFH.
In Table 2 they are also compared to the values found in a purified system consisting in AT III (a00 nM), thrombin (20 nM) and heparin (varying concentrations). The rate constants of LMWH are considerably lower than those of standard heparin. This is especially clear when the results are expressed on a molar basis. The activity of heparins in plasma is about 15-35% of that observed in a purified system. This can be attributed to the lower susceptibility of endogenous thrombin to AT Ill(-heparin) action and/or to the presence of heparin binding proteins in plasma.
In Thble 3 we summarize the data on the breakdown constants of factor IIu, IXo, X,, and XIo in purified systems. The activity of heparins decreases in the order llu, Xo, IXo and XIu. The exception is EMT 967 that has no activity towards thrombin.
In order to see whether EMT 967 competes with EMT 966 for AT III under our experimental circumstances, we added increasing amounts of EMT 967 to a fixed amount of EMT 966, it did not cause any significant change in the activity of the EMT 966 (Fig.2) .
Influence of LMW Heparins on the Thrombin Generation in Plasma
The formation of thrombin in plasma was measured in the presence and absence of PK10169, EMT 966 and EMT 96'7,both The anti II^ and anti Xu activities were estimated according to (4) In section A the data are on weight basis, in section B they are calculated on basis of the molar concentration, using the molecular weights from Thble 1. R : Ratio of the rate constant in a purified system over that in plasma Table 3 The second order breakdown constants of various ciotting proteases with heparins in a purified system in the extrinsic system using thromboplastin as a trigger and in the intrinsic system using kaolin and phospholipid as a trigger. Because EM'f 967 is partially adsorbed onto kaolin at the usual concentration of 25 pglml of kaolin we used 2.5 p.glml. This still ensures normal contact activation but heparin adsorption is negligible.
As shown in Fig. 3 , 0.6 pg/ml and 1.2 pg/ml of PK10169 inhibit respectively 50% and 68% of the thrombin burst via the extrinsic pathway and 40"h and 58% of thrombin in intrinsic pathway.
In Fig.4 we can see that 0.2 pglml and 0.6 pg/ml of EMT 966 inhibit respectively 31% andT2Yo in the extrinsic system and 44"h and 74Yo in the intrinsic system. Fll^l 967 proves much less active. It was necessary to increase its concentration up to 5 pg/ml to obtain significant inhibition.
The question now arises whether the inhibition of the thrombin burst is due to inhibition of prothrombin activation or to increased thrombin decay.
-)L
Influence of LMW Heparins on the Prothrombinase Activity in Plasma
Using the pseudo first order rate constants of inhibition of thrombin by antithrombin III (k1) expressed in Fig. 1 and the value of 0.23 for the decay constant of thrombin (k2) due to o2-macroglobulin (1), we calculated the prothrombinase activity from the thrombin generation curves.
The data are shown in Thble 4. In the extrinsic pathway, EMT 966 causes its inhibition by thrombin scavenging without inducing an important inhibition of prothrombinase in the extrinsic system. If thus acts exactly like standard heparin (2) , EI|I4T 967 is different. Only at high concentrations it inhibits the thrombin peak, this inhibition must be attributed to the inhibition of prothrombinase or to a decreased prothrombinase generation because there is no influence on thrombin decay. PK10169 appears to inhibit by increased scavenging of thrombin as well as by prothrombinase inhibition (Thble a, Fig.5 ). The inhibitions are expressed in 7" of an uninhibited control run in parallel Thr. : Thrombin: Pase: Prothrombinase
Influence of LMWH on Thrombin Generation in Platelet-Rich Plasma
In an attempt to investigate the action of our LMW heparins in a situation nearer to the in vivo circumstances we measured thrombin generation in platelet rich plasma (PRP).
As previously found for unfractionated heparin (2, 7) we observed that PK10169 induces a prolongation of the lag phase before the appearance of the thrombin burst. Contrary to standard heparin, PK10169 inhibits also the peak of thrombin as shown in Fig.6 . One of the subfractions of PK10169, EMT 966 has the same behaviour but EMT 967 is hardly efficient in the range of concentrations that is present in PK10169 (Fig.6 ).
Discussion
We have described before tlrat neither unfractionated heparin nor a number of LMW heparins seem to cause a significant inhibition of prothrombinase in plasma clotting via the extrinsic pathway (2). This was a surprising finding in view of the fact that conventionally measured anti Xo activities of LMWHs, when compared to that of UFH, are higher then the respective antithrombin activities. In fact, the only LMWHs that inhibit prothrombinase activity to a significant extent without influencing thrombin breakdown were those that, like the Choay pentasaccharide, do not show antithrombin activity We therefore proposed the existence of two classes of heparin, those active against thrombin but hardly against prothrombinase (S heparin) and those inactive against thrombin but active against prothrombinase (P heparin) (2, 3) .
In this article we describe that PK10169. a LMWH with a mean molecular weight of 4,500 daltons does inhibit prothrombinase but also increases the AT III dependent breakdown of thrombin in plasma. This raises the question of whether there exist heparins of a mixed P & S type. Alternatively preparations that show a mixed type behaviour may indeed be mixtures of P type and S type molecules.
We separated PK10169 in a high (6.5 kDa) and a lower (3 kDa) molecular weight fraction The low molecular weight fraction (EMT967) showed a pure P type behaviour, i.e. no thrombin inhibition but a persistent antiprothrombinase activity at relatively high concentration (>5 pg/ml) The higher molecular weight fraction (EMT 966) obtained the characteristics of an S type heparin, i.e. persistent antithrombin activity and low antiprothrombinase activity. It appears therefore more likely than not that the mixed type behaviour of PK10169 is due to its being a mixture of P and S type heparins. It must be noticed however, that whereas P type heparins (i. e. pentasaccharide and EMT 967) have no antithrombin activity, S type heparins always have a residual antiprothrombinase activity that shows up at higher concentrations. This can partly be attributed to inhibition of the positive feedback reactions, i. e. the activation of factor V and VIIL AIso these preparations may always be contaminated by P type heparins. It cannot be excluded, however, that S type heparins have an inherent antiprothrombinase activity that is obscured by the far more outspoken antithrombin activity. The differences of the mode of action of LMWHs on isolated factors, even when added back to plasma as in the conventional anti IIu and anti Xu tests, and on factors generating in clotting plasma remain intriguing. At the moment we cannot offer an explanation.
If in PPP, within the group of S type heparins, there is no difference in the mode of action of UFH and LMWH, an important difference appears as soon as PRP is tested. We have shown before that up to 0.5 U/ml of UFH is practically completely inactivated by activated platelets. This makes that UFH in PRP postpones the thrombin burst but hardly inhibits it (7). As we can see from Fig. 6 . PK10169 and EMT 966 both postpone and inhibit the generation of thrombin in PRP. Preliminary experiments suggest that this is due to a lower suceptibility of LMWHs to pf4. This is in good accordance with observations showing pf4 susceptibility to decrease with decreasing molecular weight 18-12).
In Fig.6 is seen that EMT 967, when added in a concentration of 0.7 pg/ml does not significantly inhibit thrombin generation in PRP. When the same amount is added to 1.4 pg/ml of EMT 966 it enhances the inhibition caused by EMT 966. The likely explanation is that F.MT 967 binds to pf4 and neutralizes it so that more EMT 966 is left in free form. This may be an example of a general mechanism by which LMWHs that in itself are inactive may, in PRP, potentiate the action of active heparin components.
